Chondroitin Sulfate Inhibitor Screen for Neural-Regeneration Drugs

神经再生药物的硫酸软骨素抑制剂筛选

• 批准号: 7154308
• 负责人: Charles Alexander Glass
• 金额: $ 11.49万
• 依托单位: ZACHARON PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-18 至 2008-06-17
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7154308
• 关键词: antibody; cell line; chondroitin sulfates; high throughput technology; injury; nervous system regeneration; scars; spinal cord injury; toxin

DESCRIPTION (provided by applicant): In accordance with the National Institute of Neurological Disorders and Stroke (NINDS) priorities, the goal of this proposal is to develop a system to discover drugs that have the potential to reduce scarring after spinal cord injury. In the United States, approximately 10,000 new cases of traumatic spinal cord injury occur each year. The cost of care for these patients is estimated to exceed $9 billion per year. Due to the lack of neural regeneration these patients are left with long term sensory and motor disabilities. Neural regeneration is limited by the glial scar that forms following injury. Evidence indicates that chondroitin sulfate (CS) is a component of the scar that inhibits repair. Small molecule inhibitors of CS biosynthesis have the potential to block the formation of the inhibitory scar following an injury. This application proposes to develop a novel high- throughput screening method to discover CS biosynthetic inhibitors. Approximately 10,000 new cases of traumatic spinal cord injury occur each year in the United States. The cost of care for these patients is estimated to exceed $9 billion per year. Neural regeneration is considerably limited by the glial scar that forms following injury. We propose a novel method to discover drug candidates that alter the glial scar in order to promote neural regeneration following spinal cord injury.

描述（由申请人提供）：根据国家神经疾病和中风研究所（NINDS）的优先事项，本提案的目标是开发一个系统，以发现有可能减少脊髓损伤后瘢痕形成的药物。在美国，每年约有10，000例新的创伤性脊髓损伤病例发生。这些患者的护理费用估计每年超过90亿美元。由于缺乏神经再生，这些患者留下了长期的感觉和运动残疾。神经再生受到损伤后形成的胶质瘢痕的限制。有证据表明，硫酸软骨素（CS）是抑制修复的疤痕的组成部分。CS生物合成的小分子抑制剂具有阻断损伤后抑制性瘢痕形成的潜力。本申请提出开发一种新的高通量筛选方法来发现CS生物合成抑制剂。在美国，每年大约有10，000例新的创伤性脊髓损伤病例发生。这些患者的护理费用估计每年超过90亿美元。神经再生受到损伤后形成的胶质瘢痕的限制。我们提出了一种新的方法来发现改变胶质瘢痕的候选药物，以促进脊髓损伤后的神经再生。